echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > In the 2020 annual review, 20 review resources for innovative drugs were passed, and the focus was on innovative drugs with obvious clinical value and urgently-needed drugs.

    In the 2020 annual review, 20 review resources for innovative drugs were passed, and the focus was on innovative drugs with obvious clinical value and urgently-needed drugs.

    • Last Update: 2021-08-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network, June 23.
    The State Food and Drug Administration released the "2020 Drug Evaluation Report" on June 21
    .
    The "Report" shows that 20 innovative drugs passed the review in 2020
    .
    The "Report" shows that 59 new crown virus vaccines and new crown pneumonia treatment drugs registration applications were included in the special approval process and completed the technical review throughout the year
    .
    A total of 1062 applications (597 varieties) for the registration of category 1 innovative drugs were accepted, an increase of 51.
    71% over 2019
    .
    Approved 208 new drug listing applications, an increase of 26.
    83% compared with 2019
    .
    Appraisal has passed the application of 20 varieties of innovative drugs (14 category 1 chemical drugs, 4 innovative Chinese medicine drugs, and 2 innovative biological products)
    .
    Appraised and approved 72 varieties (including new-indication varieties) for the marketing applications of overseas-produced original research drugs
    .
    In terms of breakthrough therapeutic drug procedures, among the new drug marketing applications reviewed and approved by the Center for Drug Evaluation, a total of 15 applications were listed after conditional approval
    .
    Under the accelerated registration process of drugs, review resources are tilted towards innovative drugs with obvious clinical value and urgently needed drugs
    .
    For example, the registration applications included in the priority review and approval procedures include 42 children's drugs and drugs for rare diseases, and drugs that have been approved for marketing with conditions cover diseases caused by new coronavirus infections , non-small cell lung cancer and other indications
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.